{"id":"W2620651944","doi":"10.1016/s1470-2045(17)30429-1","title":"Dabrafenib plus trametinib in patients with BRAFV600-mutant melanoma brain metastases (COMBI-MB): a multicentre, multicohort, open-label, phase 2 trial","year":2017,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Melanoma and MAPK Pathways","field":"Biochemistry, Genetics and Molecular Biology","cited_by":775,"is_retracted":false,"has_abstract":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"National Cancer Institute; Bristol-Myers Squibb","keywords":"Dabrafenib; Trametinib; Medicine; Melanoma; Asymptomatic; Clinical endpoint; Oncology; MEK inhibitor; Internal medicine; Brain metastasis; Phases of clinical research; Clinical trial; Metastatic melanoma; Cancer; Metastasis; Vemurafenib; Cancer research; Biology; MAPK/ERK pathway","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001073894,0.001930514,0.002083973,0.0003013558,0.0003264059,0.00123217,0.0006258771,0.001277471,0.004048687],"category_scores_gemma":[0.0008114746,0.0005579659,0.001752866,0.0003839065,0.0006614232,0.001190586,0.0003046026,0.002870369,0.0009952836],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001021348,"about_ca_system_score_gemma":0.0008634322,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001367297,"about_ca_topic_score_gemma":0.004532118,"domain_scores_codex":[0.9997092,0.0001224315,0.00001192541,0.0000517012,0.00002082256,0.00008385973],"domain_scores_gemma":[0.9996464,0.000062201,0.0000697324,0.00002722634,0.00002484214,0.000169678],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9135118,0.005962158,0.00209827,0.001037104,0.002384623,0.0001388161,0.0001328887,0.001422704,0.008270795,0.0002852314,0.004287895,0.06046773],"study_design_scores_gemma":[0.9286817,0.06172111,0.004618043,0.00004854617,0.0007248264,0.0001944796,0.00006409946,0.0008643386,0.0006746161,0.0003620858,0.002010925,0.00003526246],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9866635,0.006475767,0.0005005918,0.001180743,0.0003811488,0.001170651,0.001559581,0.0001306204,0.001937316],"genre_scores_gemma":[0.9860643,0.004207412,0.001138431,0.001179339,0.0002566124,0.001212184,0.002240062,0.0000364012,0.003665228],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.004048687,"threshold_uncertainty_score":0.01354414,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.06803476530507808,"score_gpt":0.3693754023310494,"score_spread":0.3013406370259713,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}